Compare LIND & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LIND | VIR |
|---|---|---|
| Founded | 1979 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Transportation Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.5B |
| IPO Year | 2011 | 2019 |
| Metric | LIND | VIR |
|---|---|---|
| Price | $29.56 | $8.59 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | ★ $22.25 | $19.43 |
| AVG Volume (30 Days) | 720.7K | ★ 1.5M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 5.97 | ★ 17.49 |
| EPS | ★ 0.09 | N/A |
| Revenue | N/A | ★ $68,556,000.00 |
| Revenue This Year | $10.98 | $270.22 |
| Revenue Next Year | $6.98 | N/A |
| P/E Ratio | $332.22 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.37 | $4.16 |
| 52 Week High | $30.44 | $11.66 |
| Indicator | LIND | VIR |
|---|---|---|
| Relative Strength Index (RSI) | 64.53 | 38.40 |
| Support Level | $16.26 | $8.40 |
| Resistance Level | $30.00 | $10.67 |
| Average True Range (ATR) | 1.17 | 0.40 |
| MACD | 0.11 | -0.11 |
| Stochastic Oscillator | 75.84 | 7.20 |
Lindblad Expeditions Holdings Inc provides expedition cruising and adventure travel services. The company operates in two segments: Lindblad and Land Experiences, of which Lindblad generates the vast majority of its revenue. It offers itineraries that feature up-close encounters with wildlife, nature, history, and culture, as well as promote guest empowerment and interactivity. It operates expeditions on intimately-scaled ships and interaction between guests, crew, and the teams of scientists, naturalists, researchers, and photographers that participate in the expeditions. Lindblad operates a fleet of twelve owned expedition ships and five seasonal charter vessels under the Lindblad brand.
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.